QIAGEN Inc.
27220 Turnberry Lane
Suite 200
Valencia
California
91355
United States
Tel: 800-426-8157
Fax: 800-718-2056
Website: http://www.qiagen.com/
About QIAGEN Inc.
QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as the "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer. The company employs more than 3,100 people in over 30 locations worldwide. QIAGEN’s North American headquarters is in Germantown, Maryland and its global headquarters is located in Hilden, Germany.
Further information about QIAGEN can be found at http://www.qiagen.com/.
114 articles about QIAGEN Inc.
-
QIAGEN posts 2017 Annual Report on Its website
4/19/2018
QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) announced today that has posted its 2017 Annual Report on its website at http://financialreport.qiagen.com.
-
QIAGEN Announces High Accuracy of Bioinformatics Solutions in Women's Health Genetic Screening
10/20/2017
QIAGEN today announced the results of a study evaluating the accuracy of the QIAGEN Clinical Insight (QCI) solution by Counsyl, a genetic screening and genetic counseling company.
-
QIAGEN Inc. Launches Fourth-Generation QuantiFERON-TB Gold Plus In The U.S.
10/6/2017
-
QIAGEN Inc. (Suzhou) Closes $25 Million A Round For Precision Medicine
7/11/2017
-
MDxHealth, Inc. Grants QIAGEN Inc. Rights To MSP Technology For QIAsure Methylation Test For Cervical Cancer Risk
6/15/2016
-
QIAGEN Inc. Integrates Quality Control Tools Into Genereader NGS System
6/1/2016
-
QIAGEN Inc. Reports Results For First Quarter of 2016
4/28/2016
-
COSMOSID Announces Partnership With QIAGEN Inc. For Microbial Analysis
2/3/2016
-
COSMOSID Announces Partnership With QIAGEN Inc. For Microbial Analysis
2/3/2016
-
QIAGEN Inc. To Supply QuantiFERON-TB Tests To Ease Tuberculin Shortage
1/26/2016
-
QIAGEN Inc. Introduces GeneReader NGS System
11/5/2015
-
QIAGEN Inc. Launches New Bioinformatics Solution For Hereditary Diseases
10/7/2015
-
QIAGEN Inc. Launches New Genetic Fingerprinting Kits For U.S. Forensic Labs
6/18/2015
-
Hitachi High-Technologies Corporation And QIAGEN Inc. Enter Into Long-Term Strategic Collaboration For Molecular Testing
6/18/2015
-
QIAGEN Inc. Reports Results For First Quarter 2015
5/7/2015
-
QIAGEN Inc. Posts 2014 Annual Report On Its Website
5/5/2015
-
BGI To Offer QIAGEN Inc. Bioinformatics Program
5/5/2015
-
QIAGEN Inc.'s TB Test Cuts Estimate Of Latent TB Incidence In China
2/11/2015
-
QIAGEN Inc. Announces First-Ever Regulatory Registration Of A Lung Cancer Companion Diagnostic Based On Liquid Biopsies
1/12/2015
-
ArcherDX Launches From QIAGEN Inc. Acquisition Of Enzymatics
1/12/2015